Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
246.8 USD | +0.10% | +4.55% | +6.69% |
Apr. 29 | Raymond James Adjusts Price Target on Danaher to $285 From $270, Keeps Outperform Rating | MT |
Apr. 26 | Danaher Insider Sold Shares Worth $5,618,569, According to a Recent SEC Filing | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.55 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.69% | 183B | B- | ||
+8.69% | 220B | B | ||
+10.90% | 133B | B- | ||
+25.41% | 107B | A- | ||
-0.38% | 63.05B | A- | ||
+12.72% | 51.74B | B+ | ||
+3.96% | 50.47B | B+ | ||
+0.40% | 40.91B | A | ||
+15.03% | 40.59B | - | ||
+26.26% | 31.91B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DHR Stock
- Ratings Danaher Corporation